X4 PHARMACEUTICALS, INC Proceeds from Issuance of Other Long-term Debt
X4 PHARMACEUTICALS, INC (XFOR) reported Proceeds from Issuance of Other Long-term Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for the quarter ending 2025-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for the quarter ending 2025-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for the quarter ending 2024-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for the quarter ending 2024-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for fiscal 2024 was $20.00M, a 11.11% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for fiscal 2023 was $22.50M.
- X4 PHARMACEUTICALS, INC proceeds from issuance of other long-term debt for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Other Long-term Debt 3 month | Proceeds from Issuance of Other Long-term Debt 6 month | Proceeds from Issuance of Other Long-term Debt 9 month | Proceeds from Issuance of Other Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $20.00M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $20.00M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $20.00M 10-Q · filed 2025-08-08 | |||
| 2023-12-31 | $22.50M 10-K · filed 2026-03-17 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-21 | |||
| 2020-12-31 | $12.39M 10-K · filed 2023-03-21 | |||
| 2019-12-31 | $9.85M 10-K · filed 2022-03-17 | |||
| 2018-12-31 | $9.91M 10-K · filed 2021-03-19 | |||
| 2017-12-31 | $6.00M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |